Corona Remedies Limited (NSE: CORONA) and Strides Pharma Science Limited (Star) (NSE: STAR) are both listed in the Pharmaceuticals industry. Corona Remedies has a market capitalisation of ₹13,278 Cr and Strides Pharma Science ₹9,557 Cr, as of 9 Nov 2026. Their P/E ratios are 71.7 and 17.2 respectively. Return on equity is 24.79% for Corona Remedies and 20.03% for Strides Pharma Science.
| Metric | Corona Remedies | Strides Pharma Science |
|---|---|---|
| NSE Symbol | CORONA | STAR |
| BSE Code | 544644 | 532531 |
| Share Price | ₹2,545.70 | ₹1,000.10 |
| Market Cap | ₹13,278 Cr | ₹9,557 Cr |
| P/E Ratio | 71.7 | 17.2 |
| Return on Equity | 24.79% | 20.03% |
| Return on Assets | 14.99% | 6.26% |
| Dividend Yield | 0.46% | 0.48% |
| Beta (1Y) | 0.24 | 0.36 |
| 1-Year Price Change | — | +1.6% |
| 3-Month Price Change | +22.3% | +0.1% |
| 52-Week Range | ₹1,336.60 – ₹2,719.30 | ₹768.65 – ₹1,260.90 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹441 Cr | ₹1,430 Cr |
| Quarterly Net Profit | ₹60 Cr | ₹134 Cr |
| Net Margin | 13.7% | 9.4% |
| EPS (Basic, Quarter) | ₹9.86 | ₹14.19 |
| Results Basis | consolidated | consolidated |
| Headquarters | Ahmedabad, Gujarat | Bengaluru, Karnataka |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
CORONA Remedies Limited, a pharmaceutical formulation company, develops, manufactures, and markets pharmaceutical products. It provides products in women’s healthcare, cardio-diabeto, pain management, urology, thyroid management, respiratory, nutraceuticals, gastroenterology, and other therapeutic areas. The company was incorporated in 2004 and is based in Ahmedabad, India.
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, and internationally. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women’s health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer …
Corona Remedies has a market capitalisation of ₹13,278 Cr, against ₹9,557 Cr for Strides Pharma Science as of 9 Nov 2026, about 1.4 times the size by market cap.
Corona Remedies has a P/E of 71.7 and Strides Pharma Science a P/E of 17.2 as of 9 Nov 2026.
Corona Remedies has a return on equity of 24.79% and Strides Pharma Science 20.03%.
Corona Remedies reported revenue of ₹441 Cr and net profit of ₹60 Cr for Q2 FY27. Strides Pharma Science reported revenue of ₹1,430 Cr and net profit of ₹134 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Pharmaceuticals > Biotechnology and Life Sciences > Pharmaceuticals on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.